Karyopharm is seeking a Manager/Senior Manager, IT Infrastructure & Operations to serve as a senior individual contributor owning the architecture, reliability, and evolution of the company’s infrastructure environment, reporting to the VP, Information Technology. This is a hands-on role operating with a high degree of autonomy, partnering across IT, Security, and the business to design and run scalable, secure infrastructure across a mix of cloud and legacy systems in a regulated environment.
This individual will lead complex initiatives end-to-end, drive modernization, and improve operational maturity across cloud and on-prem environments. Operating within a lean IT team, the role requires strong ownership, hands-on execution, and the ability to mentor others and influence infrastructure strategy without direct people management.
Key Responsibilities
Technical Leadership & Execution
Infrastructure Strategy & Modernization
Operational Excellence & Reliability
Security, Compliance & Risk Management
Cross-Functional Collaboration & Influence
Required Qualifications
Preferred Certifications
At Karyopharm, base pay is one part of a competitive total rewards package that includes comprehensive benefits (medical, dental, vision, 401(k), and more), equity and the potential to receive annual target bonuses. Actual pay is based on factors such as location, experience, skills, education, and internal equity. We maintain broad salary ranges to reflect market conditions and the specialized nature of our work. The anticipated base salary range for this position is $130 K - $175 K USD.
This is a uniquely exciting time to join Karyopharm Therapeutics where we are pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. We are building upon an established commercial foundation in multiple myeloma while advancing the potential of selinexor across additional hematologic and solid tumor cancers including myelofibrosis and TP53 wild-type endometrial cancer, areas where patients continue to face significant unmet needs.
Our lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1) and is approved in the U.S. for adults with relapsed or refractory multiple myeloma, with approvals in more than 50 countries and territories outside the U.S. We are also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor.
As we prepare for our next phase of growth, we are continuing to invest in critical capabilities across the organization to support future opportunities and deepen our impact in oncology. We are looking for talented people who are motivated by meaningful work, energized by growth and momentum, and excited by the opportunity to help shape what comes next in a collaborative, fast-moving environment where individual contributions are visible and valued.
Learn more at Karyopharm Therapeutics.
Software Powered by iCIMS
www.icims.com